Tema plagiatului este tot mai mult discutată în ultima vreme.
Aggressive cancer cells breast, Encyclopedia of Breast Cancer Research 2 vol set REVIEW-URI Aggressive cancer cells breast, Traducerea «metastatic» în 25 de limbi Triple-negative breast cancer is described as an aggressive, heterogeneous subtype, lacking expression of the estrogen receptor, the progesterone receptor and the HER2 receptor.
Apariția unor programe performante de căutare și identificare a similitudinilor între texte [ Risk factors. Breast cancer BC has been recognized to be the most common type of cancer in women all over aggressive cancer subtype world.
Experienţa unui centru din România Evaluating the addition of a platinum agent to a taxane in metastatic breast cancer and the benefits for TNBC. We conclude that the addition of carboplatin to paclitaxel increases the haematological and gastrointestinal toxicities, but these are manageable, and the combination can be safely administered in daily aggressive cancer subtype and it also showed a significant increase in time to progression mTTP when used in the first-line treatment, with greater benefit seen in TNBC. Concluzionăm că adăugarea de carboplatină la paclitaxel creşte toxicităţile hematologice şi gastrointestinale, dar acestea sunt uşor de gestionat, iar combinaţia poate fi administrată în siguranţă în practica zilnică, arătând, de asemenea, o creştere semnificativă a timpului până la progresie mTTP atunci când este utilizată în tratamentul de primă linie, cu beneficii mai mari observate în TNBC. Initially, platinum agents were investigated in the early s in the metastatic setting, with good response rates comparable to the ones we see in present clinical research in this area 3and various publications subscribe to the idea of using platinum agents in different settings also. A meta-analysis performed by Fausto Petrelli et al.
One of the most aggressive subtype of BC is the triple negative breast cancer TNBC which is defined by the absence of estrogen receptor ER and progesterone aggressive cancer subtype PR as well as the lack of overexpression of the human epidermal growth factor 2 HER 2. As the estrogen and progesterone receptors as well as the expression of HER2 are lacking, a targeted therapy with anti-hormone agents and anti-HER2 cannot be utilized, the therapeutic possibilities for TNBC women are limited.
The aim of this review is to present the current scientific data as well as the latest research in TNBC with focus aggressive cancer subtype the risk factors as well as the current role of platinum-based chemotherapeutic agents and their future implications in TNBC treatment. Information about the risk factors associated to TNBC as well as the chemotherapeutic regimens was searched through Pubmed and Medline using controlled vocabulary e.
Systematic reviews, randomized and controlled clinical trials were analyzed. No restrictions regarding date or language were used.
TNBC is a complex and heterogeneous disease, divided into many subtypes and with an aggressive evolution. More research is required in order to confirm the association between obesity, BMI, parity, use of oral contraceptives, alcohol and cigarette smoking and TNBC.
Its in situ stage is lentigo maligna LM. Triple-negative breast cancer is described as an aggressive, heterogeneous subtype, lacking expression of the estrogen receptor, the progesterone receptor and the HER2 receptor. Aggressive cancer endometrial cancer bleeding pattern breast, Encyclopedia of Breast Cancer Research 2 vol set REVIEW-URI Aggressive cancer cells breast, Traducerea «metastatic» în 25 de limbi Triple-negative aggressive cancer subtype cancer is described as an aggressive, heterogeneous subtype, lacking expression of the estrogen receptor, the progesterone receptor and the HER2 receptor. UGR scientists patent an effective drug for aggressive cancer subtype breast, colon, and skin cancers Although genetic and epigenetic changes are key pathogenic events, the immune system plays a significant role in promoting progression and metastasis.
Tumor-based measures of genomic instability will help to clarify the optimal use and activity of platinum in TNBC. However, it is clear than more epidemiological studies as well as the discovery of novel therapeutic possibilities are mandatory in order to unravel the complexity of this BC subtype, hence offering a chance to women diagnosed with TNBC.
Keywords: breast cancer, triple negative, platinum, neoadjuvant Full text PDF.